At a glance
ClinicalIndex Comparison RecordN/ACompleted· 158 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Observational, Post-authorization, Cross-sectional Study to Evaluate the Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea·observational·Posted Jun 9, 2011·Updated Apr 18, 2016
In Brief
An observational study for Diffuse Large B-cell Lymphoma. Completed, enrolled 158 participants across 56 sites.
Detailed Summary
The purpose of this study is to evaluate the prognostic value of clinical and biological factors in patients with refractory/relapsed Diffuse Large B-Cell Lymphoma.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiffuse Large B-cell Lymphoma
CountriesSpain
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2009
Primary CompletionMar 2011
First PostedJun 2011
TodayJul 2026
First PostedJun 9, 2011
Enrollment StartFeb 1, 2009
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 15.1 years ago